ARTICLE SUMMARY:
Medtech veterans Ken Nelson and Daniel O’Mahony describe the common reasons medtech start-ups fail before reaching profitability or a successful exit.
For every medtech company that makes headlines with an oversubscribed IPO or multibillion-dollar acquisition, there are many more that never produce a return for their investors. The potential causes of death are plentiful: poor clinical trial design, technical failures, reimbursement barriers, commercialization mistakes, intellectual property deficiencies, critical skill gaps, and more.
